Brexpiprazole
Phase 1Completed 0 watching 0 views this week💤 Quiet
30
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
ADHD
Conditions
ADHD, Autism, Bipolar I Disorder, Conduct Disorder, Oppositional Defiant Disorder
Trial Timeline
Oct 10, 2017 → May 21, 2018
NCT ID
NCT03292848About Brexpiprazole
Brexpiprazole is a phase 1 stage product being developed by Lundbeck for ADHD. The current trial status is completed. This product is registered under clinical trial identifier NCT03292848. Target conditions include ADHD, Autism, Bipolar I Disorder.
Hype Score Breakdown
Clinical
10
Activity
5
Company
7
Novelty
3
Community
2
Clinical Trials (11)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05504486 | Approved | Withdrawn |
| NCT04830215 | Approved | Completed |
| NCT04258839 | Phase 3 | Completed |
| NCT03548584 | Phase 3 | Completed |
| NCT03287869 | Phase 3 | Completed |
| NCT03292848 | Phase 1 | Completed |
| NCT03238326 | Phase 3 | Completed |
| NCT01944969 | Phase 3 | Terminated |
| NCT01942785 | Phase 3 | Completed |
| NCT01942733 | Phase 3 | Completed |
| NCT01810783 | Phase 3 | Completed |
Competing Products
20 competing products in ADHD